Quantcast

Latest Intercell Stories

2013-09-30 23:26:29

Reportbuyer.com just published a new market research report: Needle-Free Delivery: Technology And Market 2013-2023. (PRWEB) September 30, 2013 Report Details Needle-free delivery - discover technological and commercial prospects What does the future hold for the needle-free delivery market? Visiongain's report gives you forecasted revenues to 2023. It explains trends, opportunities and prospects for the overall needle-free injection technology market. There is urgent need for...

2011-12-01 14:29:16

One-third of the world's people have latent TB Statens Serum Institut and Aeras today announced the initiation of the first Phase I clinical trial of a new candidate TB vaccine designed to protect people latently infected with TB from developing active TB disease. The trial is being conducted by the South African Tuberculosis Vaccine Initiative (SATVI) at its field site in Worcester, in the Western Cape province of South Africa. Dr. Hassan Mahomed is the principal investigator. "Two...

2011-05-10 01:53:00

VIENNA, May 10, 2011 /PRNewswire/ -- Today, the biotech-vaccine company Intercell AG (VSE: ICLL) announced its financial results for Q1 and presented an update on the Company's development programs. Financial Results Year-on-year revenue growth of 19.7% driven by strong IXIARO®/JESPECT® sales revenues Restructuring process progressing successfully - operating loss reduced by 33.1% Higher sales and reduced spending lead to reduced net loss of EUR...

2011-05-05 01:53:00

VIENNA, May 5, 2011 /PRNewswire/ -- Today Intercell AG (VSE: ICLL) announced that the company's Supervisory Board has appointed Thomas Lingelbach as new Chief Executive Officer (CEO) for Intercell, effective May 10, 2011. At the same time, Gerd Zettlmeissl, current CEO, will resign to pursue other personal and professional interests. Under his excellent leadership, Intercell received international approval for the novel Japanese Encephalitis vaccine,...

2011-04-11 01:32:00

WHITEHOUSE STATION, N.J., and VIENNA, April 11, 2011 /PRNewswire/ -- Merck (NYSE: MRK), known as MSD outside the United States and Canada, and Intercell AG (VSE: ICLL) today announced that following a pre-specified interim analysis from the Phase II/III clinical trial evaluating V710, an investigational vaccine for the prevention of Staphylococcus aureus (S. aureus) infection, the independent Data Monitoring Committee (DMC) recommended suspension of enrollment. Although the trial did not...

2011-04-01 01:18:00

VIENNA, April 1, 2011 /PRNewswire/ -- Today Intercell AG (VSE: ICLL) announced that it has agreed with Novartis to advance Intercell's investigational Pseudomonas aeruginosa vaccine into a confirmatory clinical efficacy trial in ventilated ICU (Intensive Care Unit) patients. The planned double blind study is powered to show a clinically meaningful and statistically significant reduction in overall mortality between the vaccine and control group and envisages enrolling about 800 subjects....

2011-03-01 01:35:00

VIENNA, March 1, 2011 /PRNewswire/ -- Today Intercell AG (VSE: ICLL) announced its financial results for Q4 and the preliminary results for the full financial year 2010 and presented an update on the Company's development programs. Increase in IXIARO®/JESPECT® sales by approximately 66% to EUR 12.8m for the full year 2010, due to increased sales in key travel markets and to U.S. military. EUR 255.2m net loss for the full year 2010 resulting mainly from...

2011-02-23 02:05:00

VIENNA, Feb. 23, 2011 /PRNewswire/ -- Intercell AG (Vienna Stock Exchange, ICLL) ("Intercell" or the "Company") today announced that it successfully placed EUR 33.0m of Senior Unsecured Convertible Notes (the "Notes") in a private placement transaction, which was increased due to investor demand. The Notes have a conversion price of EUR 11.43 reflecting a premium of 20.0% to the volume weighted average price and of 18.4% to the closing share price of Intercell's shares on February 22,...

2011-02-22 12:00:00

VIENNA, Feb. 22, 2011 /PRNewswire/ -- Intercell AG (VSE: ICLL) today announced the offering of EUR 30.8m of Senior Unsecured Convertible Notes (the "Notes"). The Notes will be placed in a non-public offering to institutional investors through an accelerated overnight book-building process which starts today after market close and is expected to be completed on Wednesday, February 23, 2011. The expected terms include a coupon of up to 6% per annum and a conversion premium to today's...


Word of the Day
ramage
  • Boughs or branches.
  • Warbling of birds in trees.
Related